Table of Content

1. Executive Summary

2. Disease Epidemiology
2.1 Novel Coronavirus Etiology and Disease Pathogenesis
2.2 COVID-19 Clinical Features – Signs and Symptoms
2.3 Disease Epidemiology and Epidemic Statistics for Major Countries

3. Global Clinical Trial Analysis of COVID-19 Therapeutics and Vaccines
3.1 Global Clinical Trial Analysis, By Region
3.1.1 United States
3.1.2 Europe
3.1.3 Others
3.2 Global Clinical Trial Analysis, By Product Type
3.2.1 Small Molecules
3.2.2 Biologics
3.2.2.1 Blood & Plasma Derivatives
3.2.2.2 Monoclonal Antibodies
3.2.2.3 Vaccines
3.2.2.4 Others
3.3 Global Clinical Trial Analysis, By Phase of development
3.3.1 Clinical Phase I (Active trial & Discontinued Trials)
3.3.2 Clinical Phase II (Active trial & Discontinued Trials)
3.3.3 Clinical Phase III (Active trial & Discontinued Trials)
3.3.4 Clinical Phase IV (Active trial & Discontinued Trials)
3.4 Global Clinical Trial Analysis, By Route of Administration
3.4.1 Route of Administration
3.4.1.1 Oral
3.4.1.2 Intravenous
3.4.1.3 Subcutaneous
3.4.1.4 Other Route of Administration
3.5 Global Clinical Trial Analysis, By Type of Sponsor
3.5.1 Pharma/Biotech Company
3.5.2 Academic Research/Institution
3.5.3 Others such as Government Organizations and CROs

4. Top 10 Late Staged Therapeutics and Vaccine Clinical Trials Analysis
3.6 Company Overview
3.7 Trial Description (including trial design)
3.8 Trial Status & Trial Enrollment
3.9 Trial Results
3.10 Licensing and Collaboration Agreements
3.11 Milestones & Future Plans

5. Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals

1. Regulatory Framework in the USA

2. Regulatory Framework in EU & Other Countries

6. Recommendations & Conclusion